ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2019 Pre-Market Earnings Guidance

Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday morning. The company provided EPS guidance of 5.06-5.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.14. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $209.67 million.

A number of analysts have recently weighed in on ANIP shares. ValuEngine raised shares of ANI Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, November 19th. Guggenheim started coverage on ANI Pharmaceuticals in a report on Thursday, September 12th. They issued a buy rating and a $76.00 target price on the stock. Zacks Investment Research lowered ANI Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, November 12th. Finally, BidaskClub raised ANI Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. ANI Pharmaceuticals currently has a consensus rating of Hold and an average target price of $86.40.

ANIP opened at $59.43 on Tuesday. The company’s 50 day moving average is $67.04 and its 200-day moving average is $72.11. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $86.96. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.30. The company has a market cap of $744.99 million, a P/E ratio of 12.89 and a beta of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. During the same quarter in the prior year, the company earned $1.29 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 1.2% compared to the same quarter last year. On average, equities analysts forecast that ANI Pharmaceuticals will post 4.58 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

See Also: What is net income?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.